Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grown Rogue International's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 37.52.
Grown Rogue International's Days Inventory for the
three
months ended in Mar. 2026 was 124.02.
Grown Rogue International's Days Payable for the
three
months ended in Mar. 2026 was 34.93.
Therefore, Grown Rogue International's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 126.61.
Grown Rogue International (FRA:1VF0) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Grown Rogue International Cash Conversion Cycle Related Terms
Grown Rogue International Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grown Rogue International Cash Conversion Cycle Chart
FRA:1VF0 vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grown Rogue International's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grown Rogue International Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grown Rogue International's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Grown Rogue International's Cash Conversion Cycle falls into.
Grown Rogue International Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Grown Rogue International's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grown Rogue International (FRA:1VF0) has a Cash Conversion Cycle of 126.61 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grown Rogue International and its competitors.
Is Grown Rogue International's Cash Conversion Cycle too high?
Grown Rogue International's current Cash Conversion Cycle is 126.61. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Grown Rogue International's value of 126.61 is 13.2% below this industry median. Overall, Grown Rogue International has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Grown Rogue International's Cash Conversion Cycle compare to ZTS and UTHR?
Grown Rogue International's Cash Conversion Cycle of 126.61 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Grown Rogue International's value of 126.61 is 13.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grown Rogue International's current Cash Conversion Cycle of 126.61 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grown Rogue International and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grown Rogue International's current Cash Conversion Cycle is 126.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grown Rogue International stock overvalued right now?
Grown Rogue International (FRA:1VF0) has a current Cash Conversion Cycle of 126.61. The stock's GF Value™ is €0.36, compared to a current price of €0.36 — trading 0.6% below its estimated fair value. The current Cash Conversion Cycle is 126.61 and 13.2% below the Drug Manufacturers industry median of 145.92. Grown Rogue International's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Grown Rogue International (FRA:1VF0), the current Cash Conversion Cycle is 126.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grown Rogue International (FRA:1VF0) Overvalued in 2026?
Based on GuruFocus' analysis, Grown Rogue International stock appears to be undervalued.
The current stock price of €0.36 is trading 0.6% below its estimated GF Value™ of €0.36.
Key valuation signals for FRA:1VF0:
Cash Conversion Cycle: 126.61
GF Value™: €0.36 vs. price of €0.36 (0.6% below fair value)
Industry Position: 13.2% below the Drug Manufacturers median
No single metric tells the full story. See the FRA:1VF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grown Rogue International Inc is engaged in the business of growing and selling cannabis products. Its primary cannabis product produced and sold is cannabis flower. Geographically, the company generates a majority of its revenue from the United States. The company has identified three operating segments: the Oregon segment represents cannabis production and sales activities in Oregon; the Michigan segment represents cannabis production and sales activities in Michigan; and the New Jersey segment represents cannabis production and sales activities in New Jersey.
49GF Score
Get the complete analysis for FRA:1VF0
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1VF0 has been successfully added to your 
